Trial Profile

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endothelial stem cell therapy CellProThera (Primary)
Indications Myocardial infarction
Focus Adverse reactions; First in man
Acronyms EXCELLENT
Sponsors CellProthera

Most Recent Events

08 Jul 2024 According to a CellProthera media release ,the company have successful agreement with BioCardia for treatment of acute myocardial infarction (AMI) led by CellProthera, as well as plans to continue the relationship into Phase III.
14 May 2024 According to a BioCardia media release, study results in post-myocardial infarction are expected to be presented during the European Society of Cardiology Heart Failure Congress, May 14 to 16, 2024.
25 Apr 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com